"Chromosome engineering" technology = cutting, connecting, and transferring chromosomes.
Antibodies recognize foreign substances from the outside, activating the immune system and producing B cells. If you want to create human antibodies against a specific protein, due to ethical issues, it is not possible to administer the protein to humans to obtain antibody-producing cells. Traditionally, to produce antibodies against humans, the target protein was administered to animals like mice, whose immune systems would respond, allowing for the collection of antibody-producing cells. Then, the antigen recognition site would be analyzed, and the human antibody region would be substituted in a process called "humanization." When constructing human antibody-producing cells, the human antibody-producing gene is introduced into rat cells via a plasmid. The plasmid integrates into the host's chromosomes, which poses a problem as it can disrupt the function of other genes. Our company has successfully introduced a large human antibody-producing artificial chromosome vector into rat cells using chromosome engineering technology, allowing it to be stably maintained independently. 【Features】 ■ Rapid acquisition of human antibody-producing cells is possible ■ Increased potential to obtain antibody drug candidates *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
【Specifications】 ■ Capable of autonomous replication and distribution like natural chromosomes ■ Stably maintained at a constant copy number ■ No overexpression or loss of expression occurs ■ No restrictions on the size of introduced DNA *For more details, please refer to the catalog or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
TransChromosomics Co., Ltd. is a Tottori University-based biotech venture established with the aim of developing drug discovery and drug discovery support tools, leveraging the know-how of chromosome engineering technology acquired by CEO Mitsuo Oshimura during his 30 years of research. Using cutting-edge chromosome engineering technology, the company conducts chromosome modification, iPS/ES cell production, genetically modified mouse and rat production, animal testing, and antibody production, among other activities.
